New flu vaccine passes first safety check in seniors
NCT ID NCT07421050
First seen Feb 27, 2026 · Last updated May 20, 2026 · Updated 10 times
Summary
This early-stage trial tested the safety of a new flu vaccine with an added ingredient (adjuvant) to boost immune response. It involved 80 volunteers aged 65 and older, who were monitored for side effects over 12 months. The goal was to see if the vaccine is safe enough for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gucheng County Center for Disease Control and Prevention
Xiangyang, Hubei, China
Conditions
Explore the condition pages connected to this study.